Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis
The Efficacy and Safety of Humanized Antibody Targeting the Interleukin-4 Receptor Alpha Subunit (IL-4Rα) in Patients With Uncontrolled Seasonal Allergic Rhinitis Under Standard Treatment： A Randomized, Double-Blind, Placebo-controlled IIT Study
Beijing Tongren Hospital
120 participants
Mar 18, 2024
INTERVENTIONAL
Conditions
Summary
Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.
Eligibility
Inclusion Criteria1
- Voluntarily sign the informed consent form.
Exclusion Criteria1
- Have any condition that are not suitable for participating in this study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Interleukin-4 receptor was injected subcutaneously.
Placebo was injected subcutaneously.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06300203